1 / 18

Ranolazine : from the treatment of chronic ischemic heart disease to the diabetic patient

Ranolazine : from the treatment of chronic ischemic heart disease to the diabetic patient Edoardo Mannucci Diabetes Agency Careggi teaching hospital, Firenze, Italy. CARDIOVASCULAR THERAPY AND DIABETES.

barclay-palmer
Télécharger la présentation

Ranolazine : from the treatment of chronic ischemic heart disease to the diabetic patient

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ranolazine: from the treatment of chronic ischemic heart disease to the diabetic patient Edoardo Mannucci Diabetes Agency Careggi teaching hospital, Firenze, Italy

  2. CARDIOVASCULAR THERAPY AND DIABETES • Manycardiovasculardrugs and procedures show a reducedefficacy in patients with diabetes (e.g., ASA, or PTCA) • Manycardiovasculardrugsincreasebloodglucose in patients with diabetes (e.g., beta-blockers or diuretics)

  3. CARISA trial: ranolazine vs placebo, 12 weeks Patients (N=189) with stable angina – 189 with diabetes

  4. 927 patients with T2DM Stable angina

  5. Recurrentischemia; patients with ACS

  6. Group 1: ranolazine 3 wk Group 2: ranolazine 2 wk, pbo 1wk Group 3: placebo 3 wk

  7. ENDOTHELIAL ACTIONS OF RANOLAZINE • Antiinflammatoryaction • Antioxidantproperties • Direct inhibition of receptors mediating late sodium channel current on endothelial cells • Improvement of glucose control

  8. 927 patients with T2DM Stable angina

  9. Patients with ACS

  10. MECHANISMS OF GLUCOSE LOWERING ACTION • Reducedglucogeonesis due to inhibition of lipidoxydation (?) • Increasedinsulinsensitivity (?)

  11. CARISA trial: ranolazine vs placebo, 12 weeks Patients (N=189) with stable angina – 189 with diabetes

  12. STZ-diabetic mice, ranolazine vs vehicle

  13. Oralglucosetolerance test STZ-diabetic mice, ranolazine vs vehicle

  14. MECHANISMS OF GLUCOSE LOWERING ACTION • Reducedglucogeonesis due to inhibition of lipidoxydation (?) • Increasedinsulinsensitivity(?) • Stimulation of insulinsecretion (via beta-cell Na channels) (?) • Increased beta-cell mass in the long term (?)

  15. STZ-diabetic mice, ranolazine vs vehicle

  16. STZ-diabetic mice, ranolazine vs vehicle

More Related